WEHI-539Bcl-xL inhibitor,potent and selective CAS# 1431866-33-9 |
- BM-1074
Catalog No.:BCC2235
CAS No.:1391108-10-3
- Arctiin
Catalog No.:BCN1090
CAS No.:20362-31-6
- 2,3-DCPE hydrochloride
Catalog No.:BCC2384
CAS No.:418788-90-6
- TW-37
Catalog No.:BCC2257
CAS No.:877877-35-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1431866-33-9 | SDF | Download SDF |
| PubChem ID | 71297207 | Appearance | Powder |
| Formula | C31H29N5O3S2 | M.Wt | 583.72 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO | ||
| Chemical Name | 5-[3-[4-(aminomethyl)phenoxy]propyl]-2-[(8E)-8-(1,3-benzothiazol-2-ylhydrazinylidene)-6,7-dihydro-5H-naphthalen-2-yl]-1,3-thiazole-4-carboxylic acid | ||
| SMILES | C1CC2=C(C=C(C=C2)C3=NC(=C(S3)CCCOC4=CC=C(C=C4)CN)C(=O)O)C(=NNC5=NC6=CC=CC=C6S5)C1 | ||
| Standard InChIKey | JKMWZKPAXZBYEH-JWHWKPFMSA-N | ||
| Standard InChI | InChI=1S/C31H29N5O3S2/c32-18-19-10-14-22(15-11-19)39-16-4-9-27-28(30(37)38)34-29(40-27)21-13-12-20-5-3-7-24(23(20)17-21)35-36-31-33-25-6-1-2-8-26(25)41-31/h1-2,6,8,10-15,17H,3-5,7,9,16,18,32H2,(H,33,36)(H,37,38)/b35-24+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | WEHI-539, has high affinity (subnanomolar) and selectivity for BCL-XL and potently kills cells by selectively antagonizing its prosurvival activity. WEHI-539 has a high affinity for BCL-XL (IC50 = 1.1 nM). | |||||
| Targets | BCL-XL | |||||
| IC50 | 1.1 nM | |||||
| Cell experiment[1]: | |
| Cell lines | Human colon cancer cell |
| Preparation method | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
| Reacting condition | 1 μM, 24h |
| Applications | Limiting dilution analysis with CSCs that were pre-treated with ABT-737, ABT-199 or WEHI-539 revealed that ABT-737 and WEHI-539 both were sufficient to decrease clonogenic capacity, whereas ABT-199 did not affect clonogenic growth. As WEHI-539 is selective for BCLXL, this points to a dependency of CSCs on BCLXL for survival. Importantly, ABT-737- or WEHI-539-induced loss of clonogenicity could be restored when BCLXL was ectopically overexpressed. When spheroid cultures were treated with ABT-737 or WEHI-539 compounds, CSCs were effectively sensitized toward oxaliplatin and other chemotherapeutic agents. |
| References: 1. Colak S, Zimberlin CD, Fessler E et al. Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. Cell Death Differ. 2014 Jul;21(7):1170-7. | |
WEHI-539 Dilution Calculator
WEHI-539 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.7132 mL | 8.5658 mL | 17.1315 mL | 34.263 mL | 42.8288 mL |
| 5 mM | 0.3426 mL | 1.7132 mL | 3.4263 mL | 6.8526 mL | 8.5658 mL |
| 10 mM | 0.1713 mL | 0.8566 mL | 1.7132 mL | 3.4263 mL | 4.2829 mL |
| 50 mM | 0.0343 mL | 0.1713 mL | 0.3426 mL | 0.6853 mL | 0.8566 mL |
| 100 mM | 0.0171 mL | 0.0857 mL | 0.1713 mL | 0.3426 mL | 0.4283 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
WEHI-539 is a small-molecule inhibitor of BCL XLwith an IC50 value of 1.1 nM [1].
WEHI-539 was designed as a BCL-XLinhibitor with high affinity. It interacted the with the binding groove of BCL-XLwith a Kd value of 0.6 nM. In MEF cells lacking MCL-1, WEHI-539 induced apoptosis which was evidenced by the release of mitochondrial cytochrome cand caspase-3 processing. In BCL-XLoverexpressed MEF cells, WEHI-539 showed EC50 value of 0.48 μM. WEHI-539 also significantly induced apoptosis of the platelets purified from mice. Besides that, WEHI-539can not kill MEF cells lacking BAK because the cell death mediator BAK is regulated by BCL-XLand MCL-1. [1].
References:
[1] Lessene G, Czabotar P E, Sleebs B E, et al. Structure-guided design of a selective BCL-XL inhibitor. Nature chemical biology, 2013, 9(6): 390-397.
- (S)-Tedizolid
Catalog No.:BCC1294
CAS No.:1431699-67-0
- KN-92 hydrochloride
Catalog No.:BCC1681
CAS No.:1431698-47-3
- CCT241533 hydrochloride
Catalog No.:BCC1463
CAS No.:1431697-96-9
- SB-408124 Hydrochloride
Catalog No.:BCC1929
CAS No.:1431697-90-3
- OTSSP167
Catalog No.:BCC4314
CAS No.:1431697-89-0
- AT7867 dihydrochloride
Catalog No.:BCC1378
CAS No.:1431697-86-7
- AT7519 trifluoroacetate
Catalog No.:BCC1377
CAS No.:1431697-85-6
- gamma-secretase modulator 3
Catalog No.:BCC1585
CAS No.:1431697-84-5
- CAL-130 Hydrochloride
Catalog No.:BCC1441
CAS No.:1431697-78-7
- CAL-130
Catalog No.:BCC1440
CAS No.:1431697-74-3
- UNC1999
Catalog No.:BCC4552
CAS No.:1431612-23-5
- H-D-Ala-OMe.HCl
Catalog No.:BCC3199
CAS No.:14316-06-4
- K02288
Catalog No.:BCC5084
CAS No.:1431985-92-0
- 3'-O-Galloylmyricitrin
Catalog No.:BCN8268
CAS No.:143202-36-2
- WAY 267464 dihydrochloride
Catalog No.:BCC7813
CAS No.:1432043-31-6
- Nyasicol 1,2-acetonide
Catalog No.:BCN6879
CAS No.:1432057-64-1
- Catalponol methylthiomethyl ether
Catalog No.:BCC8905
CAS No.:1432057-74-3
- 10-Acetoxyscandine
Catalog No.:BCN7035
CAS No.:1432058-90-6
- 3-(3-Hydroxy-3-methylbutanyl)-2,4,6-trihydroxybenzophenone
Catalog No.:BCC8588
CAS No.:1432062-53-7
- 8-Isomulberrin hydrate
Catalog No.:BCC8789
CAS No.:1432063-35-8
- 6-O-Acetylcoriatin
Catalog No.:BCN7048
CAS No.:1432063-63-2
- 10-O-Acetylisocalamendiol
Catalog No.:BCN7071
CAS No.:1432064-69-1
- (Z)-3-Hydroxy-5-methoxystilbene
Catalog No.:BCN6688
CAS No.:143207-76-5
- 7-Geranyloxy-5-methoxycoumarin
Catalog No.:BCN5806
CAS No.:1432075-68-7
Human Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199.[Pubmed:27030982]
PLoS One. 2016 Mar 31;11(3):e0152607.
Human embryonic stem cells (hESCs) are hypersensitive to genotoxic stress and display lower survival ability relative to their differentiated progeny. Herein, we attempted to investigate the source of this difference by comparing the DNA damage responses triggered by the topoisomerase I inhibitor camptothecin, in hESCs, human induced pluripotent stem cells (hiPSCs) and hESCs-derived neuroprogenitors (NP). We observed that upon camptothecin exposure pluripotent stem cells underwent apoptosis more swiftly and at a higher rate than differentiated cells. However, the cellular response encompassing ataxia-telangiectasia mutated kinase activation and p53 phosphorylation both on serine 15 as well as on serine 46 resulted very similar among the aforementioned cell types. Importantly, we observed that hESCs and hiPSCs express lower levels of the anti-apoptotic protein Bcl-2 than NP. To assess whether Bcl-2 abundance could account for this differential response we treated cells with ABT-263, WEHI-539 and ABT-199, small molecules that preferentially target the BH3-binding pocket of Bcl-xL and/or Bcl-2 and reduce their ability to sequester pro-apoptotic factors. We found that in the absence of stress stimuli, NP exhibited a higher sensitivity to ABT- 263 and WEHI-539 than hESCs and hiPSCs. Conversely, all tested cell types appeared to be highly resistant to the Bcl-2 specific inhibitor, ABT-199. However, in all cases we determined that ABT-263 or WEHI-539 treatment exacerbated camptothecin-induced apoptosis. Importantly, similar responses were observed after siRNA-mediated down-regulation of Bcl-xL or Bcl-2. Taken together, our results suggest that Bcl-xL contrary to Bcl-2 contributes to ensure cell survival and also functions as a primary suppressor of DNA double-strand brake induced apoptosis both in pluripotent and derived NP cells. The emerging knowledge of the relative dependence of pluripotent and progenitor cells on Bcl-2 and Bcl-xL activities may help to predict cellular responses and potentially manipulate these cells for therapeutic purposes in the near future.
